DMARD Selection in Sjögren's Syndrome

Disease Severity-Based Approach

The European League Against Rheumatism (EULAR) notes that several immunomodulatory agents tested in Sjögren's showed marginal benefits or unacceptable adverse event rates 1, 2
For patients with mild systemic manifestations, hydroxychloroquine 200-400 mg/day may be considered, though evidence for clinical efficacy is weak 1, 2, 3
For patients with symptomatic interstitial lung disease (ILD) with moderate-to-severe impairment, first-line maintenance therapy includes mycophenolate mofetil (MMF) or azathioprine when long-term steroid use is contemplated and steroid-sparing immunosuppression is required 4, 5, 6, 7, 8, 9
Initial treatment for symptomatic ILD typically includes systemic corticosteroids (0.5-1.0 mg/kg) for symptomatic ILD, especially organizing pneumonia 4, 5, 6, 7, 8, 9
Following initial corticosteroid treatment, MMF or azathioprine should be used as first-line maintenance drugs 4, 5
Azathioprine requires testing for thiopurine methyltransferase (TPMT) activity/genotype before initiating to reduce risk of life-threatening leukopenia, and monitoring for drug-induced pneumonitis, GI upset, hepatotoxicity, and bone marrow suppression 4, 5, 8, 9
MMF requires monitoring for nausea, diarrhea, hepatotoxicity, and bone marrow suppression 4, 5, 8, 9

Rituximab (1 g IV every 15 days x2) may be considered for severe, refractory systemic disease, with best indications including vasculitis, cryoglobulinemia-associated MALT lymphoma, other marginal zone lymphomas, and diffuse large B-cell lymphoma 1, 2, 3, 10, 8
Studies of over 400 patients showed rituximab efficacy in reducing ESSDAI scores, achieving organ-specific responses, and reducing glucocorticoid doses 1, 2, 3
Calcineurin inhibitors (cyclosporine or tacrolimus) are alternative second-line options 4, 5, 8

High-dose IV methylprednisolone is recommended for acute respiratory failure or rapidly progressive ILD 10
Cyclophosphamide or rituximab should be considered in addition to high-dose corticosteroids for patients with acute/subacute hypoxic respiratory failure despite initial therapies 10
Pneumocystis jirovecii prophylaxis with cyclophosphamide is necessary, and the IV route should be used to reduce bladder cancer risk 10

No head-to-head comparisons exist between immunosuppressive agents in Sjögren's syndrome, preventing definitive recommendations of one agent over another except based on patient-specific factors and safety profiles 3
The lack of licensing for biologics significantly limits their use in clinical practice despite having the highest level of evidence among tested drugs 1, 2, 3
There is a risk of drug-induced lung disease with methotrexate, leflunomide, rituximab, cyclophosphamide, sulfasalazine, and TNF-alpha inhibitors, and consideration of bronchoscopy/biopsy and medication withdrawal is necessary if patients are progressive or refractory 10
Over 95% of reported cases using immunosuppressive agents in primary Sjögren's received concomitant glucocorticoids, making assessment of monotherapy efficacy difficult 3

For Sjögren's syndrome patients who cannot tolerate or have not responded to hydroxychloroquine, treatment should be stratified by disease severity, with symptomatic management using topical therapies and muscarinic agonists for sicca features alone, immunosuppressive agents combined with glucocorticoids for moderate systemic disease, and rituximab for severe refractory systemic manifestations, as recommended by the European League Against Rheumatism 11, 12

Topical cyclosporine A or topical corticosteroids are recommended for refractory dry eyes requiring more intensive ophthalmological management, according to the American College of Rheumatology 13, 14
Oral muscarinic agonists, such as pilocarpine or cevimeline, improve subjective ocular outcomes and can be added to topical therapy, as suggested by the European League Against Rheumatism 11, 13

Short-term NSAIDs, no longer than 7-10 days, are recommended for acute episodes of inflammatory articular pain, as advised by the American College of Rheumatology 12
Physical activity and aerobic exercise should be the first-line intervention for chronic non-inflammatory pain, with demonstrated improvement in fatigue, depression, and aerobic capacity, according to the European League Against Rheumatism 11

Methotrexate is recommended as a first-line immunosuppressive agent, with an evidence level of 1b, as suggested by the American College of Rheumatology 12
Glucocorticoid doses should be minimized to less than 7.5 mg/day prednisone equivalent for chronic maintenance and withdrawn when possible, as recommended by the European League Against Rheumatism 12

Rituximab should be considered for severe organ-threatening disease refractory to standard immunosuppressive agents, as advised by the American College of Rheumatology 12
Cyclophosphamide can be used as an alternative second-line option for severe organ-threatening disease or as rescue therapy, according to the European League Against Rheumatism 12

Concomitant fibromyalgia or chronic fatigue syndrome should be identified using standardized tools, as these influence treatment decisions and outcomes, as recommended by the American College of Rheumatology 11, 14